Immunity and cancer

Home > CALYM > Immunity and cancer

Research topics & objectives

Alterations of the innate immunity associated with cancers. Immune co-signalling and co-stimulation molecules. The role of the immune system in the microenvironment of lymphoproliferation.. Acquired immune deficiencies linked to cancer. PI-3K signalling pathway. Biotherapy immunomonitoring in cancer research.

Lymphoma sub-types

  • T-cell lymphomas
  • Follicular lymphomas
  • Hodgkin lymphomas
  • Diffuse large B-cell lymphomas

Key words

Co-signalling molecules, Microenvironment, Innate immunity, Immune deficiency associated with cancer

Daniel Olive Innovation Lymphome
Daniel Olive Marseille Cancer Research Centre

INSERM UMR 1068 Marseille Cancer Research Centre

Lymphomes B Diffus à grandes cellules
Expertise

BIOLOGICAL TARGETS AND IN VITRO/IN VIVO/EX VIVO MODELS

Targets

  • Co-signalling molecules and innate immunity in cancer.
  • Molecule families CD28/B7 (CD28, CTLA-4, PD-1, ICOS, BTLA) and their ligands (CD80, CD86, PD-L1, PD-L2, ICOSL, BTN3A), and the family TNF/TNR (HVEM/TNFRSF14, LIGHT/TNFSF14).

Models

  • Ex-vivo cultures.
  • Immunodeficient mice.
  • KO and KI models.

BLOOD AND TISSUE BIOMARKERS

Co-signalling molecules and lymphomas.

EARLY ACTIVITY PHARMACODYNAMIC SIGNALS

T cell co-stimulation and phosphatidyl-inositol 3’-kinase (PI-3K) signalling pathway.

TOOLS, PROCESSES AND PLATFORMS LINKED TO THE CLINICAL RESEARCH

  • Immunohistochemistry.
  • Generation of monoclonal antibodies.
  • IBiSA cancer immunomonitoring platform (K-Cytof).
  • Advanced Flow cytometry.
  • Regional somatic molecular oncogenetics platform.

INNOVATING TECHNOLOGY

  • Generation of monoclonal antibodies.
  • ADCC NK test in the in vitro models of cells from lymphoma patients.
  • K-Cytof (Helios).
  • Development of serum biomarkers.
  • RNAseq.
  • Polychromatic flow cytometry.

Platforms & technical resources

  • Immunomonitoring in cancer research: phase 1 studies.
  • Preclinical models.
  • Works on patient samples.
  • Polychromatic flow cytometry.
  • IHC.

R&D offer

  • Collaborative projects.
  • Immunology expertise associated with cancer.
  • Implementation of immunomonitoring projects.
  • Training in the context of Master and Doctorate degrees, including professional Master degrees.
  • Flow cytometry.
  • Access to immunological databases from lymphoma patients.
  • ADCC NK test in the in vitro models of cells from lymphoma patients.
  • Immune biomarker analysis (flow cytometry).